Stopping or reducing beta-blockers for people with HFpEF
DEPRESCRIBE-HFPEF
This project will see if safely stopping or lowering beta-blocker medicines helps older adults with heart failure with preserved ejection fraction feel and work better day-to-day.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11251615 on NIH RePORTER |
What this research studies
You would join if you are an adult with HFpEF who is taking a beta-blocker but do not have a clear reason to stay on it; participants are followed closely and monitored for safety. People will be assigned to a plan that slowly reduces or stops the beta-blocker under medical supervision or to usual care, with frequent check-ins. Researchers will measure symptoms, exercise ability, heart rate response, and quality of life using tests, wearable/heart monitoring, and questionnaires over follow-up. The team will watch carefully for side effects, worsening heart failure, or other problems and provide prompt medical care if needed.
Who could benefit from this research
Good fit: Adults with heart failure with preserved ejection fraction who are currently taking beta-blockers without a clear guideline-based indication and who are clinically stable would be ideal candidates.
Not a fit: People with reduced ejection fraction (HFrEF), a recent heart attack, certain arrhythmias, or another clear medical reason for beta-blockers are unlikely to benefit and should not stop their medicine for this project.
Why it matters
Potential benefit: If successful, stopping unnecessary beta-blockers could improve exercise tolerance, reduce symptoms, and boost quality of life while lowering medication burden for people with HFpEF.
How similar studies have performed: Beta-blockers clearly help people with HFrEF, but evidence in HFpEF is limited or mixed, so safely stopping them in HFpEF is a relatively new and not-yet-proven approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Goyal, Parag — Weill Medical Coll of Cornell Univ
- Study coordinator: Goyal, Parag
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.